Abstract
The major risk factor associated with repeated platelet transfusions is alloimmunization. Its management represents one of the greatest remaining clinical and research challenges in the field of platelet transfusion therapy. This is particularly true because current approaches to the treatment of leukemias and various solid tumors are now focussed on the administration of intensive, repetitive courses of postremission chemotherapy necessitating successful platelet support for a prolonged time. Moreover, once alloimmunization has supervened and histocompatible donors cannot be identified there are no proven approaches for the management of bleeding complications in thrombocytopenic patients. Thus, any practical means by which the rate or the speed of alloimmunization could be minimized would be of considerable clinical importance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies. 63 administration of leukocyte-poor blood components. Exp Hematol 1981;9:77–83.
Gmür J, von Felten A, Osterwalder B, et al. Delayed alloimmunization using random single donor platelet transfusions: A prospective study in thrombocytopenic patients with acute leukemia. Blood 1983;62:473–9:.
Dausset J, Rapaport FT. Transplantation antigen activity of human blood platelets. Transplant 1966;4:182–93.
Mincheff M, Meryman HT. Stimulation by allo-Ia requires a product of ly- sosomal processing. XII Int Cong Transplantation Soc. Sidney, 1988:177.
Marrack P, Kappler J. T-cells can distinguish between allogeneic major histocompatibility complex products on different cell types. Nature 1988; 332:840–3.
Brand A, Claas FHJ, Voogt PJ, Wasser MNJM, Eernisse JG. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988;54:160–6.
Murphy MF, Metcalfe P, Thomas H, et al. Use of leukocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986;62:529–34.
Schiffer CA, Ducher JP, Aisner J, et al. Randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;62:15–20.
Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964–9.
Sniecinski, O’Donell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988;71:1402–7.
Saarinen UM, Kekomäki R, Siimes MA, Myllylä G. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990;75:512–7.
Curtoni ES, Scudeller G, Mattiuz PL, Savi M, Ceppellini R. Anti-HLA-antibody evolution in recipients of planned transfusions. Tissue Antigens 1972;2:415–26.
Ferrara GB, Tosi RM, Azzolina G, Longo A. HLA unresponsiveness induced by weekly transfusions of small aliquots of whole blood. Transplant 1974;17:194–8.
Slichter SJ, O’Donnell MR, Weiden PL. Canine platelet alloimmunization: The role of donor selection.Br J Haematol 1986;63:713–27.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Gmür, J., Schanz, U., Burger, J., Reichlin, M., Müller, E., Oelz, O. (1991). Is Leukocyte Depletion Important in the Prevention of Alloimmunization by Random Single Donor Platelet Transfusion?. In: Sibinga, C.T.S., Kater, L. (eds) Advances in haemapheresis. Developments in Hematology and Immunology, vol 25. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3904-9_24
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3904-9_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6742-0
Online ISBN: 978-1-4615-3904-9
eBook Packages: Springer Book Archive